NantKwest
9920 Jefferson Boulevard
Culver City
California
90232
United States
Tel: 1-844-696-5235
Website: http://www.nantkwest.com/
89 articles about NantKwest
-
Researchers are continuing to develop next-generation therapeutics and oral vaccines that could overcome some vaccine hesitancy. Here are some of the top producers.
-
Simply put, an antibody is a large, Y-shaped blood protein produced by plasma cells that the immune system uses to take down pathogens like bacteria – and of course, viruses like SARS-CoV-2.
-
All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote “FOR” the Pending Merger With ImmunityBio
2/25/2021
The NantKwest Special Committee and the NantKwest Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 8, 2021 at 9:30 a.m. Pacific Time
-
ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity
2/11/2021
FDA authorized the expansion of the active Phase 1 COVID-19 vaccine trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost, to induce comprehensive immune protection through CD4+ and CD8+ T cells to both Spike (S) and Nucleocapsid (N) antigens, as well as generate systemic and mucosal antibodies
-
NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
1/13/2021
Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment options In initial Cancer Moonshot QUILT trials of haNK and avelumab (PD-L1 checkpoint inhibitor) completed in 2019, median overall survival rate more than doubled compared to historical controls (eight months versus three months)
-
NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021
1/6/2021
NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39 th Annual J.P. Morgan Healthcare Conference on January 13, 2021
-
ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company
12/21/2020
Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms
-
Shares of NantKwest were up more than 27% in premarket trading after the company announced a stock-for-stock reverse merger with privately-held ImmunityBio.
-
NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare Conference
11/18/2020
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32 nd Annual Piper Sandler Healthcare conference, which takes place December 1-3, 2020. NantKwest Executive Chairman Patrick Soon-Shiong, M.D., and Chief Executive Officer Rich Adcock will parti
-
ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study
11/10/2020
First two cohorts fully enrolled; Low dose cohort reports no serious adverse events (SAE), high dose cohort safety analysis ongoing Subject screening is ongoing for Phase I expansion cohorts Phase 2 / 3 hAd5 COVID-19 trial in design
-
BioSpace Movers & Shakers, Oct. 30
10/30/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
NantKwest Names Richard Adcock Chief Executive Officer
10/26/2020
Experienced Six Sigma healthcare executive bolsters leadership team at key juncture; will work closely with Dr. Patrick Soon-Shiong who will serve as Executive Chairman
-
ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation COVID-19 Vaccine Candidate Delivering Both Spike and Nucleocapsid of SARS-CoV-2
10/21/2020
First patient receives ImmunityBio’s second-generation hAd5 COVID vaccine, delivering both outer S (spike) protein and inner N (nucleocapsid) leading to potential long-term T cell and antibody immunity to the SARS-CoV-2 virus
-
NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All Approved Standards of Care
10/6/2020
Third cohort added to independently evaluate the efficacy of NantKwest’s PD-L1 t-haNK natural killer cells plus ImmunityBio’s IL-15 superagonist Anktiva™ (N-803) in third-line or greater therapy for patients with locally advanced or metastatic pancreatic cancer. Two other cohorts for first-line maintenance and second-line randomized against standards of care chemotherapy. 40 patients are currently enrolled in or being evaluated for the Phase 2
-
NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit
9/21/2020
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6, 2020 at 12:50 PM ET. The conference presentation will be available on the NantKwest website, NantKwes
-
NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
6/29/2020
NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock (4,811,500 shares at a price to the public of $9.50 per share and 3,710,000 shares at a price of $12.12 per share to NantKwest’s chairman,
-
NantKwest Announces Pricing of Public Offering of Common Stock - June 25, 2020
6/25/2020
NantKwest, Inc., a clinical-stage, natural killer cell-based therapeutics company, announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock.
-
NantKwest Announces Proposed Public Offering of Common Stock - June 24, 2020
6/24/2020
NantKwest, Inc., a clinical-stage, natural killer cell-based therapeutics company, announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
-
NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested
6/10/2020
NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested NantKwest’s antibody-targeted NK cell line, haNK, which is engineered for increased antibody-dependent cell-mediated cytotoxicity and activation, showed increased resistance to hypoxic conditions as seen in suppressive tumor microenvironments N
-
NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference
5/26/2020
NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET. The presentation will be webcast live and can be accessed through the NantKwest and ImmunityBio websites, NantKwest.com and ImmunityBio.com . An archived replay will be available on the